Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The "beta-fluorine effect" in the non-metal hydride radical deoxygenation of fluorine-containing nucleoside xanthates.

Siddiqui MA, Driscoll JS, Abushanab E, Kelley JA, Barchi JJ Jr, Marquez VE.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):1-12.

PMID:
10772699
3.

Decay rates of anti-HIV dideoxynucleotides in tissue culture systems: a simple correction for the effect of cell replication.

Ahluwalia GS, Dedrick RL, Driscoll JS, Morrison PF, Gao WY, Johns DG.

Drug Metab Dispos. 1997 Jul;25(7):893-6.

4.

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, Driscoll JS, Mitsuya H.

Antimicrob Agents Chemother. 1997 Jun;41(6):1313-8.

5.

Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice.

Ruxrungtham K, Boone E, Ford H Jr, Driscoll JS, Davey RT Jr, Lane HC.

Antimicrob Agents Chemother. 1996 Oct;40(10):2369-74.

6.

Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.

Driscoll JS, Siddiqui MA, Ford H Jr, Kelley JA, Roth JS, Mitsuya H, Tanaka M, Marquez VE.

J Med Chem. 1996 Apr 12;39(8):1619-25.

PMID:
8648601
7.
8.

Acute cardiotoxicity of the Anti-HIV dideoxynucleoside, F-ddA, in the rat.

Donzanti BA, Kelley JA, Tomaszewski JE, Roth JS, Tosca P, Placke M, Singer A, Yarrington JT, Driscoll JS.

Fundam Appl Toxicol. 1995 Sep;27(2):167-76.

PMID:
8529811
9.
10.

Conformational changes of small molecules binding to proteins.

Nicklaus MC, Wang S, Driscoll JS, Milne GW.

Bioorg Med Chem. 1995 Apr;3(4):411-28.

PMID:
8581425
11.

Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.

Ford H Jr, Siddiqui MA, Driscoll JS, Marquez VE, Kelley JA, Mitsuya H, Shirasaka T.

J Med Chem. 1995 Mar 31;38(7):1189-95.

PMID:
7707321
12.

Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity.

Ford H Jr, Driscoll JS, Hao Z, Dobyns KA, Rommel ME, Stowe E, Anderson JO, Plowman J, Waud WR, Johns DG, et al.

Biochem Pharmacol. 1995 Jan 18;49(2):173-80.

PMID:
7840794
13.
14.

Effect of anti-HIV 2'-beta-fluoro-2',3'-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production.

Tsai CH, Doong SL, Johns DG, Driscoll JS, Cheng YC.

Biochem Pharmacol. 1994 Oct 7;48(7):1477-81.

PMID:
7945448
15.

National Cancer Institute Drug Information System 3D database.

Milne GW, Nicklaus MC, Driscoll JS, Wang S, Zaharevitz D.

J Chem Inf Comput Sci. 1994 Sep-Oct;34(5):1219-24.

PMID:
7962217
18.
19.

Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.

Siddiqui MA, Driscoll JS, Marquez VE, Roth JS, Shirasaka T, Mitsuya H, Barchi JJ Jr, Kelley JA.

J Med Chem. 1992 Jun 12;35(12):2195-201.

PMID:
1351945
20.

Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.

Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ Jr.

J Med Chem. 1991 Nov;34(11):3280-4.

PMID:
1956046
21.

Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.

Barchi JJ Jr, Marquez VE, Driscoll JS, Ford H Jr, Mitsuya H, Shirasaka T, Aoki S, Kelley JA.

J Med Chem. 1991 May;34(5):1647-55.

PMID:
2033591
22.

Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.

Murakami K, Shirasaka T, Yoshioka H, Kojima E, Aoki S, Ford H Jr, Driscoll JS, Kelley JA, Mitsuya H.

J Med Chem. 1991 May;34(5):1606-12.

PMID:
2033586
23.

A ring-enlarged oxetanocin A analogue as an inhibitor of HIV infectivity.

Tseng CK, Marquez VE, Milne GW, Wysocki RJ Jr, Mitsuya H, Shirasaki T, Driscoll JS.

J Med Chem. 1991 Jan;34(1):343-9.

PMID:
1992135
24.

2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.

Masood R, Ahluwalia GS, Cooney DA, Fridland A, Marquez VE, Driscoll JS, Hao Z, Mitsuya H, Perno CF, Broder S, et al.

Mol Pharmacol. 1990 Apr;37(4):590-6.

PMID:
2109183
25.

Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.

Marquez VE, Tseng CK, Mitsuya H, Aoki S, Kelley JA, Ford H Jr, Roth JS, Broder S, Johns DG, Driscoll JS.

J Med Chem. 1990 Mar;33(3):978-85.

PMID:
2106581
26.

Metabolism in human leukocytes of anti-HIV dideoxypurine nucleosides.

Fridland A, Johnson MA, Cooney DA, Ahluwalia G, Marquez VE, Driscoll JS, Johns DG.

Ann N Y Acad Sci. 1990;616:205-16.

PMID:
2078020
27.

Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma.

Kern DH, Shoemaker RH, Hildebrand-Zanki SU, Driscoll JS.

Cancer Res. 1988 Sep 15;48(18):5178-82.

28.

Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.

Marquez VE, Lim MI, Treanor SP, Plowman J, Priest MA, Markovac A, Khan MS, Kaskar B, Driscoll JS.

J Med Chem. 1988 Sep;31(9):1687-94.

PMID:
3411597
29.

2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV).

Marquez VE, Tseng CK, Kelley JA, Mitsuya H, Broder S, Roth JS, Driscoll JS.

Biochem Pharmacol. 1987 Sep 1;36(17):2719-22. No abstract available.

PMID:
3651175
30.

Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.

Kim CH, Marquez VE, Broder S, Mitsuya H, Driscoll JS.

J Med Chem. 1987 May;30(5):862-6.

PMID:
3033243
31.

Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.

Haces A, Breitman TR, Driscoll JS.

J Med Chem. 1987 Feb;30(2):405-9.

PMID:
3806621
32.

Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides.

Kelley JA, Driscoll JS, McCormack JJ, Roth JS, Marquez VE.

J Med Chem. 1986 Nov;29(11):2351-8.

PMID:
3783592
33.

Spiromustine analogues. Relationships between structure, plasma stability, and antitumor activity.

Haces A, Driscoll JS, Roth JS, Heideman RL, Kelley JA.

J Pharm Sci. 1986 Mar;75(3):313-6.

PMID:
3701619
34.

Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.

Dalal M, Plowman J, Breitman TR, Schuller HM, del Campo AA, Vistica DT, Driscoll JS, Cooney DA, Johns DG.

Cancer Res. 1986 Feb;46(2):831-8.

36.

Synthesis of 3-hydroxy-2- and -4-pyridone nucleosides as potential antitumor agents.

Mao DT, Driscoll JS, Marquez VE.

J Med Chem. 1984 Feb;27(2):160-4.

PMID:
6694165
37.

The preclinical new drug research program of the National Cancer Institute.

Driscoll JS.

Cancer Treat Rep. 1984 Jan;68(1):63-76.

PMID:
6692438
38.

Agents with potential specificity against melanotic melanoma.

Lin AJ, Kelley JA, Breitman TR, Driscoll JS.

J Med Chem. 1982 May;25(5):501-5.

PMID:
7086835
39.

Catecholamine analogs as potential antitumor agents II.

Lin AJ, Driscoll JS.

J Pharm Sci. 1981 Jul;70(7):806-8. No abstract available.

PMID:
7264934
40.

Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size.

Liu PS, Marquez VE, Driscoll JS, Fuller RW, McCormack JJ.

J Med Chem. 1981 Jun;24(6):662-6.

PMID:
7252974
41.

Pyridones as potential antitumor agents II: 4-Pyridones and bioisosteres of 3-acetoxy-2-pyridone.

Hwang DR, Proctor GR, Driscoll JS.

J Pharm Sci. 1980 Sep;69(9):1074-6.

PMID:
7411412
42.

Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase.

Marquez VE, Liu PS, Kelley JA, Driscoll JS, McCormack JJ.

J Med Chem. 1980 Jul;23(7):713-5. No abstract available.

PMID:
7401098
43.

Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds.

McCormack JJ, Marquez VE, Liu PS, Vistica DT, Driscoll JS.

Biochem Pharmacol. 1980 Mar 1;29(5):830-2. No abstract available.

PMID:
20227965
44.

Synthesis of propranolol mustard as a possible lung-specific antitumor agent.

Feyns LV, Beisler JA, Driscoll JS, Adamson RA.

J Pharm Sci. 1980 Feb;69(2):190-2.

PMID:
7359322
45.

Catecholamine analogs as potential antitumor agents.

Driscoll JS.

J Pharm Sci. 1979 Dec;68(12):1519-21.

PMID:
529042
46.

Synthesis and antitumor activity of 5-azacytosine arabinoside.

Beisler JA, Abbasi MM, Driscoll JS.

J Med Chem. 1979 Oct;22(10):1230-4.

PMID:
92567
47.

Pyridones as potential antitumor agents.

Hwang DR, Driscoll JS.

J Pharm Sci. 1979 Jul;68(7):816-9.

PMID:
458596
48.

Potential CNS antitumor agents VI: aziridinylbenzoquinones III.

Driscoll JS, Dudeck L, Congleton G, Geran RI.

J Pharm Sci. 1979 Feb;68(2):185-8.

PMID:
423089
49.

Potential CNS antitumor agents-phenothiazines II: fluphenazine analogs.

Hirata T, Peng G, Driscoll JS.

J Pharm Sci. 1978 Feb;67(2):157-62.

PMID:
621629
50.

Psychotropic drugs as potential antitumor agents: a selective screening study.

Driscoll JS, Melnick NR, Quinn FR, Lomax N, Davignon JP, Ing R, Abott BJ, Congleton G, Dudeck L.

Cancer Treat Rep. 1978 Jan;62(1):45-74.

PMID:
23898

Supplemental Content

Loading ...
Support Center